Recent Updates
Recently added Catalysts
PAHC Positive Sentiment Score: 85/100

Phibro Animal Health Corporation Completes Acquisition of Zoetis' Medicated Feed Additive Product Portfolio and Certain Water-Soluble Products TEANECK, N.J.

Key Takeaway: Phibro Animal Health Corporation has successfully completed the acquisition of Zoetis' medicated feed additive portfolio and select water-soluble products. This acquisition enhances Phibro's capabilities in animal health by complementing its existing product lineup and expanding its reach into 80 countries. The new offerings are anticipated to boost profitability and be accretive to Phibro's earnings. Financial details will be shared during the Q1 earnings call on November 7.

Market Sentiment Analysis

POSITIVE FACTORS

  • Acquisition enhances Phibro's product offerings and global reach.
  • New products aim to optimize animal health and nutrition.
  • Expected to improve profitability and diversity revenue streams.

Full Press Release Details

Health Corporation Completes Acquisition of Zoetis' Medicated Feed Additive Product Portfolio and Certain Water-Soluble Products
N.J. October 31, 2024 (Business Wire) -- Phibro Animal Health Corporation (Nasdaq:
PAHC) today announced the successful completion of the acquisition of the medicated feed additive product portfolio and certain water-soluble
products from Zoetis Inc. (NYSE:ZTS). This acquisition marks a significant step in furthering Phibro's purpose to optimize global
animal health and nutrition for better lives and a more sustainable world.
this new lineup of medicated feed additives and water-soluble products across cattle, swine and poultry will complement and expand Phibro's
species and product portfolios, helping customers meet the highest standards of animal care, prevent disease, and enhance nutrition around
the world." said Jack C. Bendheim, Chairman, President and Chief Executive Officer of Phibro Animal Health Corporation. "These
products fit Phibro's core competencies and capabilities while complementing our current lineup of vaccines, nutritional specialties
and mineral nutrition."
includes a product portfolio with more than 37 product lines sold across approximately 80 countries, six manufacturing sites in the U.S.,
Italy and China, and a team of more than 300 employees who primarily support the manufacturing and distribution activities of the business.
The agreement to acquire the business was announced on April 28, 2024.
The portfolio is expected to boost Phibro's profitability and
EBITDA margin and be accretive to its Adjusted Earnings Per Share. Additional financial details will be provided during our Q1 earning
call on November 7th.
is a win-win-win," noted Larry Miller, Phibro's Chief Operating Officer. "For our customers, it broadens the solution options and expertise that Phibro brings to support animal health globally; for consumers, it helps continue to ensure
that food is produced safely and sustainably; and for our investors, it expands and diversifies our revenue base, ultimately
generating funding to support future investment in additional fast-growing animal health product categories."
About Phibro Animal Health Corporation
Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner
with livestock producers, farmers, veterinarians, and consumers who raise or care for farm and companion animals by providing solutions
to help them maintain and enhance the health of their animals. For further information, please visit www.pahc.com.
Forward-Looking Statements
Forward-Looking Statements: This communication contains
forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical or current
fact included in this communication are forward-looking statements. Forward-looking statements discuss our current expectations and projections
relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking
statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as "aim,"
"anticipate," "believe," "estimate," "expect," "forecast," "outlook,"
"potential," "project," "projection," "plan," "intend," "seek,"
"may," "could," "would," "will," "should," "can," "can have,"
"likely," the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing
or nature of future operating or financial performance or other events. These statements are not guarantees of future performance or actions.
If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual
results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the
date on which they are made. Phibro expressly disclaims any obligation to update or revise any forward-looking statement, whether as a
result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be
found in our Quarterly Report on Form 10-Q and Annual Report on Form 10-K, including in the sections thereof captioned "Forward-Looking
Statements" and "Risk Factors." These filings and subsequent filings are available online at www.sec.gov, www.pahc.com,
or on request from Phibro.
Internet Posting of Information: We routinely post
information that may be important to investors in the "Investors" section of our website at www.pahc.com. We encourage investors
and potential investors to consult our website regularly for important information about us.
Contact for Phibro Animal Health Corporation
Phibro Animal Health Corporation
Chief Financial Officer

Frequently Asked Questions

What did Phibro Animal Health Corporation acquire?

Phibro acquired Zoetis' medicated feed additive portfolio and certain water-soluble products.

How many product lines does the new portfolio include?

The new portfolio includes more than 37 product lines sold in around 80 countries.

What benefits does Phibro expect from this acquisition?

Phibro anticipates improved profitability, enhanced EBITDA margin, and increased Adjusted Earnings Per Share.

Who is the CEO of Phibro Animal Health Corporation?

Jack C. Bendheim is the Chairman, President, and CEO of Phibro.

When was the acquisition agreement announced?

The acquisition agreement was announced on April 28, 2024.

Last updated: Oct 31, 2024